Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/B 4.08
XBI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 4.08 )
Ranked among companies with meaningful P/B only.
XBI' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 4.39
Current: 4.08
0
4.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.74
XBI's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.74 )
Ranked among companies with meaningful Dividend Yield only.
XBI' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.74
Current: 0.74
0
0.74
Yield on cost (5-Year) 0.74
XBI's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XBI: 0.74 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XBI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.74
Current: 0.74
0
0.74

More Statistics

Short Percentage of Float0.00%
52-Week Range $45.73 - 246.94
Shares Outstanding(Mil)32400032.00
» More Articles for XBI

Headlines

Articles On GuruFocus.com
Ben Graham's Congressional Hearing Apr 30 2016 
What Investors Need to Know About GM’s 1st-Quarter Earnings Apr 30 2016 
Investors Should Consider Snyder's-Lance Apr 30 2016 
U.S. Market Indexes Close Lower for the Week Apr 30 2016 
Baron Real Estate Fund's 1st-Quarter Letter Part One Apr 30 2016 
Carl Icahn Interview With CNBC Apr 30 2016 
Mattel Is a Definite Short Right Now Apr 29 2016 
Here Are PayPal’s Growth Drivers for the Next Decade Apr 29 2016 
Why Icahn Sold Apple Apr 29 2016 
Apple Is Facing a Big Problem Apr 29 2016 

More From Other Websites
Is XBI Heading Back to Where It Started in April? Apr 28 2016
Opportunities For Xtandi, Medivation’s Key Drug Apr 28 2016
Energy-Related Stocks Rose after FOMC Decision Apr 27 2016
Trader's Notebook: Responding to the Move in Dollar Futures Apr 25 2016
Trader's Notebook: Searching for Bullish Excess in the Banks Apr 22 2016
Rising Dollar Offsets Crude Prices as Major SPDR Indexes Fall Apr 21 2016
XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study Apr 21 2016
How Does XBI Compare to Its 100-Day Moving Average? Apr 21 2016
XBI Mid-Caps: Medivation Rose after Rejecting Sanofi’s Takeover Bid Apr 20 2016
SPDR Indexes across Energy and Gold Rise on Increase in Commodities Apr 19 2016
What Do Analysts Recommend for Medivation? Apr 19 2016
Return Of The Mack: This Biotech ETF Is Back Apr 19 2016
Recovery in Crude Prices Lifts Energy and Healthcare SPDR Indexes Apr 18 2016
US Dollar Is Strong despite Inflation Releasing below Forecast Apr 14 2016
Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue Apr 14 2016
Large-Cap News: Edwards Surged on SAPIENT 3 TAVR Data Apr 11 2016
Among Biotechnology ETFs, XBI Dominated the 1st Week of April Apr 11 2016
XBI Mid Caps: Alnylam to Present at Needham Healthcare Conference Apr 08 2016
Incyte Continues Its Growth Spree in 2015 Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK